• Monomethyl auristatin E in State-Aware ADC Studies

  2026-09-10

  Monomethyl auristatin E (MMAE) enables highly sensitive payload-response studies when free drug, antibody-drug conjugate delivery, and tumor cell state are evaluated separately. This workflow connects tubulin-directed cytotoxicity with the EBV-associated plasticity biology of nasopharyngeal carcinoma while clearly distinguishing established evidence from translational hypotheses.

• AR and ARv7 in TNBC: EPI-001 Evidence

  2026-09-09

  This 2025 study integrates patient immunohistochemistry, TCGA-BRCA analysis, and MDA-MB-231 experiments to examine AR and ARv7 in triple-negative breast cancer. Its findings associate ARv7, especially nuclear ARv7, with adverse outcomes and show that EPI-001 and enzalutamide modulate metastasis and epithelial–mesenchymal transition markers through pathways involving ROCK, NF-κB, and c-Myc.

• CFTRinh-172 Workflows for CFTR Transport Studies

  2026-09-09

  CFTRinh-172 enables rapid, reversible separation of CFTR channel activity from trafficking and signaling effects. This guide translates that distinction into epithelial transport workflows, surface-abundance controls, secretory diarrhea models, and practical troubleshooting strategies.

• CCCP: Mitochondrial Proton Gradient Uncoupler

  2026-09-08

  CCCP, also called carbonyl cyanide m-chlorophenyl hydrazine, dissipates the mitochondrial proton gradient and uncouples ATP production from respiratory electron flow. Its strongest research use is as a controlled bioenergetic perturbation, not as a clinical or diagnostic reagent.

• DeferoxamineB: Iron Chelation in Cancer Research

  2026-09-08

  Deferoxamine is an Fe(III)-chelating research compound used to test iron dependence, oxidative stress, and regulated cell death in biological models. DeferoxamineB supports ferroptosis-focused assay design, but results should not be interpreted as direct evidence of cuproptosis, apoptosis, or autophagy without pathway-specific controls.

• GSK621: A Practical AMPK Agonist Workflow

  2026-09-07

  GSK621 provides a direct way to interrogate AMPK-driven metabolic remodeling, mTORC1 suppression, autophagy, and apoptosis in AML and immunometabolic models. This workflow connects target engagement assays with practical optimization steps and the 25-hydroxycholesterol–AMPK pathway described in tumor-associated macrophages.

• Azithromycin Workflows for Infection Research

  2026-09-07

  Azithromycin supports practical workflows spanning bacterial infection research, resistance screening, analytical quality control, and investigational trypanosomosis studies. This guide connects its 50S-ribosome mechanism with solvent handling, impurity control, washout experiments, and assay-specific troubleshooting.

• Ibrexafungerp Activity at Vaginal pH

  2026-09-05

  The reference study tested ibrexafungerp, also known as MK 3118, against 187 vaginal Candida isolates under neutral and acidic conditions relevant to vulvovaginal candidiasis. Its central finding was that acidic pH did not materially reduce in vitro activity, including against fluconazole-resistant Candida, supporting pH-controlled susceptibility workflows while not substituting for clinical or in vivo efficacy studies.

• Potassium Channels and Renal Blood Flow in Sepsis

  2026-09-04

  The reference study shows that ATP-sensitive and calcium-activated potassium channels influence renal vascular responses during experimental sepsis, particularly when vasopressors are administered. Its combined ex vivo and in vivo design reveals that channel blockade may leave baseline renal blood flow unchanged yet worsen perfusion loss during pressor challenge.

• DeferoxamineB as a Ferroptosis Assay Probe

  2026-09-04

  DeferoxamineB is more than an iron chelator: it is a useful mechanistic probe for separating iron-dependent lipid damage from copper-driven regulated cell death. This article explains how to interpret Deferoxamine responses alongside the metabolic intervention strategy described in recent oncology research.

• AZD6482 Workflow for PI3Kβ Assays

  2026-09-03

  AZD6482 provides a selective PI3Kβ perturbation tool for platelet, metabolic, and signaling assays. This workflow connects its established use cases with RNA-FISH experiments inspired by a recent DM1 study while clearly separating validated applications from hypothesis-generating extensions.

• MCL-1’s Canonical Apoptotic Role in Breast Cancer

  2026-09-03

  The reference study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK-mediated mitochondrial apoptosis. By combining acute genetic deletion, pharmacological inhibition, and apoptosis-pathway epistasis, the work clarifies why selective MCL-1 inhibition can suppress tumor growth while also linking MCL-1 to breast cancer stem-cell activity.

• Tacrolimus (FK506): Designing Better Immune Assays

  2026-09-02

  Tacrolimus (FK506) is a highly potent calcineurin inhibitor for dissecting T-cell activation and cytokine signaling. This guide translates immunophilin biology into stronger assay controls, dosing decisions, and disease-model interpretation.

• Verapamil HCl: Calcium Signaling Workflows

  2026-09-02

  Verapamil HCl gives researchers a practical way to perturb calcium-dependent signaling while measuring viability, apoptosis, drug accumulation, and inflammatory outputs. This workflow-focused guide separates direct L-type channel effects from transporter and combination-treatment confounders in myeloma and arthritis models.

• Resiniferatoxin: Context-Aware TRPV1 Research

  2026-09-01

  Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist whose value extends beyond analgesia. This guide explains how exposure, tissue context, and assay design determine whether RTX produces calcium signaling, sensory-neuron desensitization, or durable functional silencing.

8312 records 1/555 page Next 12345 下5页 Last page